Aviance Capital Partners LLC Has $309,000 Stock Holdings in Kenvue Inc. (NYSE:KVUE)

Aviance Capital Partners LLC trimmed its holdings in shares of Kenvue Inc. (NYSE:KVUE) by 7.7% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 14,479 shares of the company’s stock after selling 1,213 shares during the period. Aviance Capital Partners LLC’s holdings in Kenvue were worth $309,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Grove Bank & Trust boosted its stake in shares of Kenvue by 438.4% during the 4th quarter. Grove Bank & Trust now owns 1,163 shares of the company’s stock worth $25,000 after buying an additional 947 shares during the last quarter. Geneos Wealth Management Inc. bought a new stake in shares of Kenvue in the 4th quarter valued at about $29,000. SRS Capital Advisors Inc. raised its holdings in shares of Kenvue by 67.4% in the 4th quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company’s stock valued at $30,000 after purchasing an additional 571 shares during the period. Fortitude Family Office LLC raised its holdings in shares of Kenvue by 106.6% in the 4th quarter. Fortitude Family Office LLC now owns 1,506 shares of the company’s stock valued at $32,000 after purchasing an additional 777 shares during the period. Finally, Ashton Thomas Securities LLC bought a new stake in shares of Kenvue in the 3rd quarter valued at about $35,000. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Kenvue Stock Performance

NYSE KVUE opened at $23.46 on Friday. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66. The firm has a market capitalization of $44.83 billion, a price-to-earnings ratio of 44.25, a P/E/G ratio of 2.62 and a beta of 1.45. The firm’s 50 day simple moving average is $21.64 and its 200 day simple moving average is $22.32. Kenvue Inc. has a 1 year low of $17.67 and a 1 year high of $24.46.

Kenvue (NYSE:KVUE) last posted its quarterly earnings results on Thursday, February 6th. The company reported $0.26 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. As a group, research analysts expect that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Wednesday, February 26th. Shareholders of record on Wednesday, February 12th were given a $0.205 dividend. The ex-dividend date was Wednesday, February 12th. This represents a $0.82 dividend on an annualized basis and a yield of 3.50%. Kenvue’s dividend payout ratio is currently 154.72%.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on KVUE. Piper Sandler upped their target price on shares of Kenvue from $24.00 to $27.00 and gave the company an “overweight” rating in a report on Monday, February 24th. Deutsche Bank Aktiengesellschaft cut shares of Kenvue from a “buy” rating to a “hold” rating and dropped their target price for the company from $25.00 to $24.00 in a report on Thursday, December 12th. Barclays lowered their price target on shares of Kenvue from $23.00 to $21.00 and set an “equal weight” rating on the stock in a report on Friday, January 17th. Citigroup lowered their price target on shares of Kenvue from $25.00 to $21.00 and set a “neutral” rating on the stock in a report on Wednesday, January 15th. Finally, Royal Bank of Canada reissued a “sector perform” rating and issued a $24.00 price target on shares of Kenvue in a report on Monday, February 3rd. One research analyst has rated the stock with a sell rating, seven have given a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average price target of $23.75.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.